Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study
IntroductionOptimise:MS is an observational pharmacovigilance study aimed at characterizing the safety profile of disease-modifying therapies (DMTs) for multiple sclerosis (MS) in a real world population. The study will categorize and quantify the occurrence of serious adverse events (SAEs) in a coh...
Main Authors: | Ed Waddingham, Aleisha Miller, Ruth Dobson, Paul M. Matthews |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.799531/full |
Similar Items
-
Herbal medicines pharmacovigilance in Iran
by: Mohammad Hadi Zarei
Published: (2022-06-01) -
Organisation of the Russian Pharmacovigilance System: Survey of Pharmacovigilance Officers
by: A. E. Krasheninnikov, et al.
Published: (2021-10-01) -
Preparation for the Inspection of the Pharmacovigilance System
by: B. K. Romanov
Published: (2021-10-01) -
The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study)
by: Arantxa Sancho-López, et al.
Published: (2023-10-01) -
Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice
by: N. Yu. Velts, et al.
Published: (2023-03-01)